Publications

2018

Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth., L. Fontan; Q. Qiao; J.M. Hatcher; G. Casalena; I. Us; M. Teater; M. Durant; G. Du; M. Xia; N. Bilchuk; S. Chennamadhavuni; G. Palladino; G. Inghirami; U. Philippar; H. Wu; D.A. Scott; N.S. Gray; A. Melnick, J Clin Invest, 2018 Oct 01, 128, 10, p.4397-4412, (2018) PubMed

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival., X. Lu; T.M. Fernando; C. Lossos; N. Yusufova; F. Liu; L. Fontan; M. Durant; H. Geng; J. Melnick; Y. Luo; F. Vega; V. Moy; G. Inghirami; S. Nimer; A.M. Melnick; I.S. Lossos, Blood, 2018 Nov 08, 132, 19, p.2026-2039, (2018) PubMed

Untangling the Role of Polycomb Complexes in Chemotherapy Resistance., C. Duy; A. Melnick, Cancer Discov, 2018 Nov, 8, 11, p.1348-1351, (2018) PubMed

Enhancer of zeste homolog 2 (EZH2) inhibitors., N. Gulati; W. Béguelin; L. Giulino-Roth, Leuk Lymphoma, 2018 Jul, 59, 7, p.1574-1585, (2018) PubMed

Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs., K.M. Noh; H. Wang; H.R. Kim; W. Wenderski; F. Fang; C.H. Li; S. Dewell; S.H. Hughes; A.M. Melnick; D.J. Patel; H. Li; D. Allis, Mol Cell, 2018 Feb 01, 69, 3, p.533, (2018) PubMed

How Biophysical Forces Regulate Human B Cell Lymphomas., F. Apoorva; A.M. Loiben; S.B. Shah; A. Purwada; L. Fontan; R. Goldstein; B.J. Kirby; A.M. Melnick; B.D. Cosgrove; A. Singh, Cell Rep, 2018 Apr 10, 23, 2, p.499-511, (2018) PubMed

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis., P.M. Dominguez; H. Ghamlouch; W. Rosikiewicz; P. Kumar; W. Béguelin; L. Fontan; M.A. Rivas; P. Pawlikowska; M. Armand; E. Mouly; M. Torres-Martin; A.S. Doane; M.T.Calvo Fernández; M. Durant; V. Della-Valle; M. Teater; L. Cimmino; N. Droin; S. Tadros; S. Motanagh; A.H. Shih; M.A. Rubin; W. Tam; I. Aifantis; R.L. Levine; O. Elemento; G. Inghirami; M.R. Green; M.E. Figueroa; O.A. Bernard; S. Aoufouchi; S. Li; R. Shaknovich; A.M. Melnick, Cancer Discov, 2018 Dec, 8, 12, p.1632-1653, (2018) PubMed

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity., H. Kunimoto; C. Meydan; A. Nazir; J. Whitfield; K. Shank; F. Rapaport; R. Maher; E. Pronier; S.C. Meyer; F.E. Garrett-Bakelman; M. Tallman; A. Melnick; R.L. Levine; A.H. Shih, Cancer Cell, 2018 Jan 08, 33, 1, p.44-59.e8, (2018) PubMed

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia., F.C. Brown; E. Still; R.P. Koche; C.Y. Yim; S. Takao; P. Cifani; C. Reed; S. Gunasekera; S.B. Ficarro; P. Romanienko; W. Mark; C. McCarthy; E. de Stanchina; M. Gönen; V. Seshan; P. Bhola; C. O'Donnell; B. Spitzer; C. Stutzke; V.P. Lavallée; J. Hébert; A.V. Krivtsov; A. Melnick; E.M. Paietta; M.S. Tallman; A. Letai; G. Sauvageau; G. Pouliot; R. Levine; J.A. Marto; S.A. Armstrong; A. Kentsis, Cancer Discov, 2018 Apr, 8, 4, p.478-497, (2018) PubMed

Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design., H. Cheng; B.M. Linhares; W. Yu; M.G. Cardenas; Y. Ai; W. Jiang; A. Winkler; S. Cohen; A. Melnick; A. MacKerell; T. Cierpicki; F. Xue, J Med Chem, 2018 Sep 13, 61, 17, p.7573-7588, (2018) PubMed